Dr. Mei Huang š, an accomplished researcher in schizophrenia and neuropharmacology, has dedicated her career to unraveling the complexities of mental health. With a Ph.D. from Shenyang Pharmaceutical University, China, she conducted pioneering postdoctoral research at Vanderbilt University, USA. Serving as a Research Assistant Professor at Northwestern University, Chicago, she’s earned accolades such as the NARSAD Young Investigator Award and CINP Young Investigator Award. š Dr. Huang’s extensive contributions extend to editorial roles and collaborative grants, investigating novel therapies for cognitive function and neurotransmitter regulation. Her passion for advancing psychiatric understanding is evident in her diverse and impactful research endeavors. š©āš¬š§ š
Profile:
Scopus
Education:
Dr. Mei Huang’s academic journey reflects a profound commitment to understanding the intricacies of medicine. š From 1994 to 1998, she pursued her Bachelor’s in Pharmacy, specializing in Chinese Traditional Medicine at the esteemed School of Chinese Traditional Medicine, Shenyang Pharmaceutical University, China. šļø Building on this foundation, she earned her Ph.D. in Neuropharmacology from the Department of Pharmacology, School of Pharmacy, Shenyang Pharmaceutical University, from September 1998 to August 2002. š Her academic pursuits showcase a seamless blend of traditional and modern medicine, setting the stage for a career dedicated to advancing neuropharmacological research. š©āš¬šæš§
Experience:
Dr. Mei Huang’s academic odyssey seamlessly transitioned from her postdoctoral roles to impactful academic appointments in prestigious institutions. š Beginning at Shenyang Pharmaceutical University, China, she thrived as a Postdoctoral Research Fellow and Teaching Assistant from August 2002 to July 2003. š« Her journey continued across continents as she pursued postdoctoral research at Vanderbilt University, USA, from August 2003 to July 2008. šŗšø Subsequently, she made significant contributions as a Research Assistant Professor at Vanderbilt University (2008ā2012) and later at Northwestern University, Chicago, where she presently serves. š Dr. Huang’s diverse roles underscore her dedication to advancing knowledge in pharmacology and psychiatry. š©āš¬šš§
Award & Honors:
Dr. Mei Huang’s exceptional contributions in schizophrenia research earned her prestigious accolades. š In 2005, she received the NARSAD Young Investigator Award from the National Alliance for Research on Schizophrenia and Depression, USA, recognizing her groundbreaking work. š The following year, in 2006, she was honored with the CINP Young Investigator Award, further solidifying her impact on neuro-psychopharmacology. š§ Her dedication continued, with another NARSAD Young Investigator Award in 2007, emphasizing her sustained excellence in advancing understanding and treatment of schizophrenia and related mental health disorders. šš©āš¬š
Publications:
- “NU-1223, a simplified analog of alstonine, with 5-HT2cR agonist-like activity, rescues memory deficit and positive and negative symptoms in subchronic phencyclidine mouse model of schizophrenia”
- Authors: Rajagopal, L., Mahjour, S., Huang, M., Scheidt, K., Meltzer, H.Y.
- Year: 2023
- Citation: Behavioral Brain Research, 454, 114614
- š§ šš
- “Repeated administration of rapastinel produces exceptionally prolonged rescue of memory deficits in phencyclidine-treated mice”
- Authors: Rajagopal, L., Huang, M., He, W., Banerjee, P., Meltzer, H.Y.
- Year: 2022
- Citation: Behavioral Brain Research, 432, 113964
- ššš
- “An autophagy-related protein Becn2 regulates cocaine reward behaviors in the dopaminergic system”
- Authors: Kim, Y.-J., Kong, Q., Yamamoto, S., Xu, M., He, C.
- Year: 2021
- Citation: Science Advances, 7(8), eabc8310
- šš§ š
- “Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action”
- Authors: Huang, M., He, W., Rajagopal, L., Grigoriadis, D.E., Meltzer, H.Y.
- Year: 2020
- Citation: Pharmacology Biochemistry and Behavior, 190, 172872
- āļøš¶āāļøš¬
- “The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice”
- Authors: Meltzer, H.Y., Rajagopal, L., Matrisciano, F., Svensson, K.A., Huang, M.
- Year: 2019
- Citation: Behavioral Brain Research, 361, 139ā150
- šÆšš
- “Activation of dopamine receptor 2 prompts transcriptomic and metabolic plasticity in glioblastoma”
- Authors: Caragher, S.P., Shireman, J.M., Huang, M., Tryba, A.K., Ahmed, A.U.
- Year: 2019
- Citation: Journal of Neuroscience, 39(11), 1982ā1993
- š§¬š§ š”
- “The role of dopamine D3 receptor partial agonism in cariprazine-induced neurotransmitter efflux in rat hippocampus and nucleus accumbens”
- Authors: Huang, M., He, W., Kiss, B., Adham, N., Meltzer, H.Y.
- Year: 2019
- Citation: Journal of Pharmacology and Experimental Therapeutics, 371(2), 517ā525
- ššš
- “TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABA A receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia”
- Authors: Rajagopal, L., Huang, M., Michael, E., Kwon, S., Meltzer, H.Y.
- Year: 2018
- Citation: Neuropsychopharmacology, 43(12), 2468ā2477
- ššš¬
- “5-HT1A partial agonism and 5-HT7 antagonism restore episodic memory in subchronic phencyclidine-treated mice: role of brain glutamate, dopamine, acetylcholine, and GABA”
- Authors: Huang, M., Kwon, S., Rajagopal, L., He, W., Meltzer, H.Y.
- Year: 2018
- Citation: Psychopharmacology, 235(10), 2795ā2808
- ššš
- “Dissecting the Functional Consequences of De Novo DNA Methylation Dynamics in Human Motor Neuron Differentiation and Physiology”
- Authors: Ziller, M.J., Ortega, J.A., Quinlan, K.A., Meissner, A., Kiskinis, E.
- Year: 2018
- Citation: Cell Stem Cell, 22(4), 559ā574.e9
- š¬š§¬š¶āāļø